Prognostic value of cell marker analysis in de novo acute myeloid leukemia

Leukemia

Volumn 8, Issue 3, 1994, Pages 388-394

  Del Poeta, Giovanni ^a,c   Stasi, Roberto ^a   Venditti, Adriano ^a   Suppo, Giovanna ^a   Aronica, Germano ^a   Bruno, Antoine ^a   Masi, Mario ^a   Tabilio, Antonio ^b   Papa, Giuseppe ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; CELL MARKER; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; HLA DR ANTIGEN; LYMPHOCYTE ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER IMMUNOLOGY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0028351277     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, Yoshida N, Morilla R. A classification of acute leukemia for the 1990s. Ann Hematol 1991;62:16-21.
2. Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer CS, McIntyre OR, Bloomfield CD. Use of surface marker to predict outcome of adult acute myeloblastic leukemia. Blood 1986;68:1232-1241.
3. Schwarzinger I, Valent P, Koller U, Marosi C, Schneider B, Haas O, Knapp W, Lechner K, Bettelheim P. Prognostic significance of surface expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1989;8:423-430.
4. Merle-Beral H, Duc LNC, Leblond V, Boucheix C, Michel A, Chastang C, Debre P. Diagnostic and prognostic significance of myelomonocytic cell surface antigens in acute myeloid leukaemia. Br J Haematol 1989;73:323-330.
5. Geller RB, Zahurak M, Craig AH, Burke PJ, Karp JE, Piantadosi S, Civin Cl. Prognostic importance of immunophenotyping in adults with acute myelocytic leukemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 1990;76:340-347.
6. Benedetto P, Mertelsmann R, Szatrowski TH. Prognostic significance of terminal deoxynucleotidyl transferase activity in acute non-lymphoblastic leukemia. J Clin Oncol 1986;4:489-495.
7. Zittoun R, Mandelli F, Willemze R, de Witte T, Tura S, Ferrini PR, Stryckmans P, Gattringer C, Petti MC, Solbu G, Vegna ML, Syciu S, for the EORTC Leukemia Cooperative Group and the GIMEMA Group. Allogeneic vs. autologous bone marrow transplantation (BMT) vs. intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML 8A). Leukemia 1992;6 (suppl 2):114-115.
8. Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, Resegotti L, Caronia F, Leoni P, Petti MC, Solbu G, Vegna ML, Suciu S, for the EORTC Leukemia Cooperative Group and the GIMEMA Group. Intensive consolidation chemotherapy vs. standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML 8B). Leukemia 1992;6 (suppl 2):76-77.
9. Resegotti L, for the GIMEMA Group. Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience. Leukemia 1992;6 (suppl 2):72-75.
10. Avvisati G, Petti MC, Spadea A, Lazzarino M,Alessandrino EP, Liso V, Specchia G, Carella AM, Falda M, Fioritoni G, Ladogana F, Mandelli F, for the cooperative group GIMEMA. Idarubicin (IDA) treatment in acute promyelocytic leukemia (APL): the GIMEMA experience. Haematologica 1991;76 (suppl 4):10.
11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:620-625.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton AG, Gralnick HR, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol 1991;78:325-329.
13. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992;79:473-476.
14. Stasi R, Tribalto M, Venditti A, Del Poeta G, Aronica G, Zaccari G, Rossi V, Maffei L, Papa G. Simultaneous occurrence of monoclonal gammopathy and acute secondary leukemia with over-expression of P-glycoprotein. Tumori 1992;78:403-406.
15. Neame PB, Soamboonsrup P, Browman GP, Meyer RM, Benger A, Wilson EC, Walker IR, Saeed N, McBride JA. Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML. Blood 1986;68:1355-1362.
16. Van der Reijden HJ, Van Rhenen DJ, Lansdorp PM, Van't Veer MB, Langenhuijsen MMAC, Engelfriet CP, Von dem Borne AEGKr. A comparison of surface marker analysis and FAB classification in acute myeloid leukemia. Blood 1983;61:443-448.
17. Pessano S, Palumbo A, Ferrero D, Pagliardi GL, Bottero L, Kai Lai S, Meo P, Carter C, Hubbell H, Lange B, Rovera G. Subpopulation heterogeneity in human myeloid leukemia determined by monoclonal antibodies. Blood 1984;64:275-281.
18. San Miguel JF, Gonzalez M, Canizo MC, Anta JP, Zola H, Lopez Borrasca A. Surface marker analysis in acute myeloid leukemia and correlation with FAB classification. Br J Haematol 1986;64:547-560.
19. Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, Maupas J, Gentilhomme O, Ehrsam A, Fiere D. Surface marker expression in adult acute myeloid leukemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989;72:161-166.
20. Drexler HG. Classification of acute myeloid leukemias - a comparison of FAB and immunophenotyping. Leukemia 1987;1:697-705.
21. Terstappen LW, Safford M, Konemann S, Loken MR, Zurlutter K, Buchner T, Hiddemann W, Wormann B. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1991;5:757-767.
22. Mitter AB, Le Beau MM, Rowley JD, Larson RA, Golomb HM, Vardiman JW. Association between morphology, karyotype, and clinical features in myeloid leukemias. Prog Pathol 1987;18:211-225.
23. Bloomfield CD, de la Chapelle A. Chromosome abnormalities in acute nonlymphocytic leukemia. Clinical and biologic significance. Semin Oncol 1987;83:372-383.
24. Ball ED, Lawrence D, Malnar M, Ciminelli N, Mayer R, Wurster-Hill D, Davey FR, Bloomfield CD. Correlation of CD34 and multidrug resistance P-170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML). Blood 1990;76 (suppl 1):999a.
25. Second MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of acute myeloid leukemias. Br J Haematol 1988;68:487-494.
26. Crist W, Boyett J, Jackson L, Vietti T, Borowitz M, Chauvenet A, Winick A, Ragab A, Mahoney D, Head D, Iyer WH, Pullen J. Prognostic importance of the pre-B cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 1989;74:1252-1259.
27. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner J, Griffin JD, Collins H, Nelson DA, Bloomfield CD. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 1987;316:1111-1114.
28. Wiersma SR, Ortega J, Sobel E, Weinberg Kl. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991;324:800-808.
29. Jensen AW, Hokland M, Jorgensen H, Justesen J, Ellegaard J, Hokland P. Solitary expression of CD7 among T-cell antigens in acute myeloid leukemia: identification of a group of patients with similar T-cell receptor beta and delta rearrangements and course of disease suggestive of poor prognosis. Blood 1991;78:1292-1300.
30. Zutter M, Martin PJ, Hanke D, Kidd PG. CD7 positive AML: association with relapse and prognosis. Blood 1988;72 (suppl 1):237a.
31. Kita K, Miwa H, Nakase K, Kawasami K, Kobayashi T, Shirakawa S, Tanaka I, Ohta C, Tsutani H, Oguma S, Kyo T, Dohy H, Kamada N, Nasu K, Uchino H. Clinical importance of CD7 expression in acute myelocytic leukemia. Blood 1993;81:2399-2405.
32. Kurtzberg J, Waldmann TA, Davey MP, Bigner SH, Moore JO, Hershfield MS, Haynes BF. CD7+,CD4-,CD8- acute leukemia: a syndrome of malignant pluripotent lympho-hematopoietic cells. Blood 1989;73:381-390.
33. Chabannon C, Wood P, Torok-Storb B. Expression of CD7 on normal human myeloid progenitors. J Immunol 1992; 149:2110-2113.
34. Zutter MM, Martin PJ, Hanke D, Kidd PG. CD7+ acute non-lymphocytic leukemia: evidence for an early multipotential progenitor. Leuk Res 1990;14:23-26.
35. Cross AH, Goorha RM, Nuss R, Behm FG, Murphy SB, Kalwinsky DK, Raimondi S, Kitchingman GR, Mirro J Jr. Acute myeloid leukemia with T-lymphoid features. A distinct biologic and clinical entity. Blood 1988;72:579-587.
36. Tien HF, Wang CH, Su IJ, Liu FS, Wu HS, Chen YC, Lin KH, Lee SC, Shen MC. A subset of acute nonlymphocytic leukemia with expression of surface antigen CD7: morphologic, cytochemical, immunocytochemical and T-cell receptor gene analysis on 13 patients. Leuk Res 1990;14:515-523.
37. Ma DDF, Scurr RD, Davey RA. Detection of a multidrug resistance phenotype in acute non-lymphoblastic leukemia. Lancet 1987;i:135-137.
38. Carulli C, Petrini M, Marini A, Ambrogi F. P-glycoprotein in acute non-lymphoblastic leukemia and in the blastic crisis of chronic myeloid leukemia. N Engl J Med 1988;319:797-798.
39. Tsuruo T, Sugimoto Y, Hamada H, Rononson I, Okumura M, Adachi K, Moroshima Y, Ohno R. Detection of multidrug resistance markers, P-glycoprotein and mdr1 mRNA, in human leukemia cells. Jpn J Cancer Res 1987;78:1415-1418.
40. Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA. Multidrug resistance in haematopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukemia. Br J Haematol 1989;72:40-44.
41. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 1991;77:50-53.
42. Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goedberg J, Vogler R, Grunwold H, Gottlieb A, Bennett J, Gottesman M, Pastan I. MDR1 transcript levels as an indicator of resistant disease in acute myelogenous leukaemia. Br J Haematol 1990;75:340-345.